A+C Meningococcal Polysaccharide Vaccine — Competitive Intelligence Brief

A+C Meningococcal Polysaccharide Vaccine (A+C Meningococcal Polysaccharide Vaccine) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Polysaccharide vaccine. Area: Immunology / Infectious Disease.

phase 3 Polysaccharide vaccine Neisseria meningitidis serogroups A and C polysaccharide capsule Immunology / Infectious Disease Biologic

Target snapshot

A+C Meningococcal Polysaccharide Vaccine (A+C Meningococcal Polysaccharide Vaccine) — Hualan Biological Engineering, Inc.. This vaccine stimulates the immune system to produce antibodies against meningococcal serogroups A and C polysaccharide antigens, providing protection against meningococcal disease.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
A+C Meningococcal Polysaccharide Vaccine TARGET	A+C Meningococcal Polysaccharide Vaccine	Hualan Biological Engineering, Inc.	phase 3	Polysaccharide vaccine	Neisseria meningitidis serogroups A and C polysaccharide capsule
A+C Vaccine	A+C Vaccine	Jiangsu Province Centers for Disease Control and Prevention	marketed	Polysaccharide conjugate vaccine	Neisseria meningitidis serogroups A and C polysaccharide capsule
MCV-AC Vaccine Group	MCV-AC Vaccine Group	Beijing Minhai Biotechnology Co., Ltd	phase 3	Conjugate vaccine	Neisseria meningitidis serogroups A and C polysaccharide capsules
PPV23 alone	PPV23 alone	Korea University Guro Hospital	marketed	Polysaccharide vaccine	Streptococcus pneumoniae capsular polysaccharides (23 serotypes)
Meningococcal A (control)	Meningococcal A (control)	International Vaccine Institute	marketed	polysaccharide vaccine	Neisseria meningitidis serogroup A capsular polysaccharide
Control 23-valent PPV	Control 23-valent PPV	Sinovac Biotech Co., Ltd	marketed	Pneumococcal polysaccharide vaccine	Streptococcus pneumoniae capsular polysaccharides (23 serotypes)
polyvalent pneumococcal vaccine	polyvalent pneumococcal vaccine	Astellas Pharma Inc	marketed	Polysaccharide vaccine

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Polysaccharide vaccine class)

1. Korea University Guro Hospital · 2 drugs in this class
2. Celgene · 1 drug in this class
3. Fakultas Kedokteran Universitas Indonesia · 1 drug in this class
4. Hoffmann-La Roche · 1 drug in this class
5. Hualan Biological Engineering, Inc. · 1 drug in this class
6. Merck Sharp & Dohme LLC · 1 drug in this class
7. University Hospital, Montpellier · 1 drug in this class
8. University of Minnesota · 1 drug in this class
9. Astellas Pharma Inc · 1 drug in this class
10. Walvax Biotechnology Co., Ltd. · 1 drug in this class